https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50124 Wed 28 Feb 2024 16:17:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48068 Wed 22 Feb 2023 16:37:56 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34714 Wed 10 Nov 2021 15:05:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46634 p < 0.05) and controls. In bronchiectasis and COPD, lower levels/better patterns of ST accumulation, as well as higher LIPA volume were associated with better clinical characteristics. These associations may be mediated by airflow limitation. Conclusions: The discordance between engagement in ST volume versus ST patterns highlights the importance of accounting for both these different yet complementary metrics. ST and LIPA are low-intensity activities associated with important clinical characteristics in people with chronic respiratory diseases. Trial registration: Not applicable.]]> Tue 29 Nov 2022 10:26:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53306 Tue 21 Nov 2023 12:03:02 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45975 Is there evidence of clinically important treatment effects for non-pharmacological therapies in cough treatment for patients with bronchiectasis?" Populations selected were all patients with bronchiectasis due to CF or non-CF bronchiectasis. The interventions explored were the non-pharmacological airway clearance therapies. The comparison populations included those receiving standard therapy and/or placebo. Clinically important outcomes that were explored were exacerbation rates, quality of life, hospitalizations, and mortality. Results: In both CF and non-CF bronchiectasis, there were systematic reviews and overviews of systematic reviews identified. Despite these findings, there were no large randomized controlled trials that explored the impact of airway clearance on exacerbation rates, quality of life, hospitalizations, or mortality. Conclusions: Although the cough panel was not able to make recommendations, they have made consensus-based suggestions and provided direction for future studies to fill the gaps in knowledge.]]> Tue 08 Nov 2022 14:39:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45138 Thu 27 Oct 2022 14:07:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29360 Thu 27 Jan 2022 15:58:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53381 Thu 23 Nov 2023 12:19:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45652 Thu 23 Mar 2023 13:58:11 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36371 Thu 17 Feb 2022 09:31:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34597 Thu 13 Jan 2022 10:31:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35398 0.05), and similar pulmonary and extrapulmonary characteristics. The associations between extrapulmonary variables and HRQoL did not differ according to diagnosis (all interactions p > 0.05). Greater anxiety and depressive symptoms, fewer steps/day and greater systemic inflammation were statistically associated with poorer HRQoL in both diseases (p < 0.05). Lower isometric leg strength in severe asthma, and greater Charlson Comorbidity Index in bronchiectasis were also associated with poorer HRQoL (p < 0.05). In the multivariable regression model performed in the combined disease groups, anxiety and depression, steps/day, systemic inflammation and isometric leg strength remained independently associated with HRQoL. Associations between extrapulmonary characteristics and SGRQ domains were stronger for the activity and impact domains, than symptoms. Conclusion: In severe asthma and bronchiectasis, extrapulmonary features including physical activity and leg strength have a significant impact on HRQoL, especially within the activity and impact domains. These features should be considered as part of the assessment of these conditions, and they may represent additional treatment targets to improve HRQoL.]]> Thu 09 Dec 2021 11:03:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:28201 Sat 24 Mar 2018 07:23:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32658 Mon 23 Sep 2019 11:23:10 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46104 adj = 9.6, 95% CI: 1.8–50.1) and the presence of Haemophilus influenzae in the BAL (OR_adj = 5.1, 95% CI: 1.4–19.1). Clinician-diagnosed asthma at final follow-up was present in 27.1% of children with PBB. A significant BDR (FEV₁ improvement >12%) was obtained in 63.5% of the children who underwent reversibility testing. Positive allergen-specific IgE (OR_adj = 14.8, 95% CI: 2.2–100.8) at baseline and bronchomalacia (OR_adj = 5.9, 95% CI: 1.2–29.7) were significant predictors of asthma diagnosis. Spirometry parameters were in the normal range. Conclusion: As a significant proportion of children with PBB have ongoing symptoms at 5 years, and outcomes include bronchiectasis and asthma, they should be carefully followed up clinically. Defining biomarkers, endotypes and mechanistic studies elucidating the different outcomes are now required.]]> Mon 21 Nov 2022 09:17:31 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43389 15 years at three hospitals: Alice Springs Hospital and Monash Medical Centre in Australia, and Middlemore Hospital in New Zealand. Data included demographics, ethnicity, sputum microbiology, radiology, spirometry, hospitalization and survival over 5 years of follow-up. Results: Aboriginal Australians were significantly younger and died at a significantly younger age than other groups. Age- and sex-adjusted all-cause mortality was higher for Aboriginal Australians (hazard ratio (HR): 3.9), and respiratory-related mortality was higher for both Aboriginal Australians (HR: 4.3) and Māori and Pacific Islander people (HR: 1.7). Hospitalization was common: Aboriginal Australians had 2.9 admissions/person-year and 16.9 days in hospital/person-year. Despite Aboriginal Australians having poorer prognosis, calculation of the FACED score suggested milder disease in this group. Sputum microbiology varied with Aspergillus fumigatus more often isolated from non-indigenous patients. Airflow obstruction was common (66.9%) but not invariable. Conclusions: Bronchiectasis is not one disease. It has a significant impact on healthcare utilization and survival. Differences between populations are likely to relate to differing aetiologies and understanding the drivers of bronchiectasis in disadvantaged populations will be key.]]> Fri 16 Sep 2022 09:37:47 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35612 Fri 13 Sep 2019 16:49:42 AEST ]]>